Healthtech and Medtech sectors see renewed investment and IPO outlook

The healthcare technology and medical device sectors are seeing a shift toward industrial maturity and renewed investment. In Europe, the IPO outlook for 2026–2028 is reopening as macroeconomic conditions stabilize. Investors are now prioritizing companies with positive free cash flow, high gross margins, and clinical validation over pure top-line growth. Underwriting standards have become more stringent, with specific annual run-rate requirements for Medtech, Healthtech SaaS, and Health AI sub-verticals.

In the private sector, healthtech funding remained active in August 2026, with four companies securing a combined $291 million. Cityblock Health led this activity with a $116 million Series E round led by General Catalyst. This funding supports Cityblock’s acquisition of Homeward Health, aimed at expanding its value-based care model into rural communities. Other notable funding rounds included $75 million for Happy Health and $50 million each for Flagler Health and Network Bio.

Data indicates that artificial intelligence has transitioned from a specialized investment category to a standard operating requirement within digital health. In the first quarter of 2026, U.S. digital health startups raised $4 billion across 110 deals.